Fulgent Genetics, Inc. (FLGT): R&D Expense
$53.91M
Year ended 2025-12-31
$56.76M
Trailing 12 months to 2026-06-30
+23.1%
3-year compound annual growth
+36.0%
5-year compound annual growth
+28.4%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $53.91M | +10.4% | 2026-02-27, From 2025-01-01 |
| 2024-12-31 | $48.82M | +17.8% | 2026-02-27, From 2024-01-01 |
| 2023-12-31 | $41.44M | +43.3% | 2026-02-27, From 2023-01-01 |
| 2022-12-31 | $28.91M | +19.4% | 2025-02-28, From 2022-01-01 |
| 2021-12-31 | $24.22M | +109.1% | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | $11.58M | +77.1% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $6.54M | +18.1% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $5.53M | +31.0% | 2020-03-13, From 2018-01-01 |
| 2017-12-31 | $4.22M | +18.7% | 2019-03-22, From 2017-01-01 |
| 2016-12-31 | $3.56M | -19.7% | 2018-03-20, From 2016-01-01 |
| 2015-12-31 | $4.43M | +750.5% | 2017-03-17, From 2015-01-01 |
| 2014-12-31 | $521.0K | n/a | 2017-03-17, From 2014-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Fulgent Genetics, Inc. (FLGT) | 2025-12-31 | $53.91M | +10.4% |
| BillionToOne, Inc. (BLLN) | 2025-12-31 | $49.38M | +34.9% |
| Castle Biosciences Inc (CSTL) | 2025-12-31 | $51.85M | -0.4% |
| CareDx, Inc. (CDNA) | 2025-12-31 | $71.43M | -1.5% |
| Veracyte, Inc. (VCYT) | 2025-12-31 | $70.81M | +2.2% |
| GRAIL, Inc. (GRAL) | 2025-12-31 | $195.79M | -39.3% |
| Caris Life Sciences, Inc. (CAI) | 2025-12-31 | $101.58M | -10.8% |
| Guardant Health, Inc. (GH) | 2025-12-31 | $364.19M | +4.7% |
| Biodesix Inc (BDSX) | 2025-12-31 | $12.00M | +25.5% |
Compare FLGT, BLLN, CSTL, CDNA side by side · Screen every company in Services-Medical Laboratories ↗